PIC still mulling Adcock’s $1.3bn CFR deal

Adcock's largest shareholder Public Investment Corporation (PIC) said it will not decide whether to support a $1.3-billion takeover proposal from Chilean drugmaker CFR Pharmaceuticals South Africa until November 4 at the earliest.

"The Public Investment Corporation has not made a decision yet, the transaction is still under consideration," PIC’s Chief Investment Officer Daniel Matjila said. "We’re doing our utmost best to have a position on Monday."

Adcock, South Africa’s largest supplier of hospital products, said yesterday shareholders representing about 45% of its shares had backed the cash and shares deal. As many as 75% of investors will have to vote in favor for the takeover to succeed, Khotso Mokhele, chairperson of Adcock's independent board, said September 11. The PIC, which oversees the pension funds of South African government workers, has a 14% stake in Adcock.

"The PIC vote will be crucial," Wayne McCurrie, a portfolio manager at Momentum Asset Management in Johannesburg. "I don’t see why the deal won’t go through at this stage, I just think some shareholders will wait until the last minute to commit."

CFR, Chile’s largest drugmaker, said in July it would pay R12.6-billion in cash and shares for Adcock as it seeks to expand in other emerging markets. The company said last month it will settle as much as 51 percent to 64.3% of the purchase through cash and the balance with new CFR shares. The transaction works out at R73.51 per Adcock share, according to both companies.

Strategic partner
The PIC would be willing to consider a strategic partner or investor if a cash offer is for 50% plus one share control of Adcock, Matjila said on July 17.

In May Matjila said  the PIC would prefer a South African company to buy the maker of Panado painkillers and Corenza cold medicine.

CFR struck agreements with Adcock’s Swiss partner Baxter Healthcare SA regarding the licensing, distribution and supply of Adcock’s hospital products and with Adcock’s black empowerment partners in South Africa, according to yesterday’s statement.

"This is a high level of support given the fragmented nature of the company’s shareholder base," Adcock said in the statement on Wednesday. "Only a limited number of requested shareholder undertakings are still to be received."

CFR has faced competition from London-based private equity firm Actis and Bidvest, a Johannesburg-based food and car sales company, in the battle to control Adcock.

CFR, which sold shares to the public in Santiago in 2011, bought Laboratorio Franco Colombiano Lafrancol SAS in December for $560-million, giving it the biggest share of the Colombian market. – Bloomberg

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Chris Spillane
Chris Spillane works from Barcelona, Spain. ✈ ✈ ✈ ✈ recovering journalist, former @business & @politicoeurope scribbler, views ≠ mine , are we having fun yet? [X] Chris Spillane has over 1885 followers on Twitter.

Related stories

Britain sets out plans for ‘no-deal’ Brexit

Document details contingency planning if Britain leaves the European Union in March with no transition deal

Antidepressant pollutants make courting birds violent — study

Male starlings sang less and were more aggressive towards females that had been given small doses of the antidepressant Fluoxetine

Fighting the spread of fake drugs in Africa

The battle to eliminate fake pharmaceutical products is being stepped up

National cancer drug shortage may last until October

Pharmaceutical companies say that delayed drug registrations by the Medicines Control Council may have played a role in stock outs.

Money can’t be the only motive for developing life-saving medicines

Will the world act now to be ready for the next big outbreak?

Activists lead fight for the right to cheaper drugs

There is a big move afoot to alert SADC members to the concessions on intellectual property rights that they can take advantage of.

Vaccine trial results due in December

If successful, it will then have to be manufactured and distributed

White men still rule and earn more

Women and black people occupy only a few seats at the JSE table, the latest PwC report has found

ANC still at odds over how to tackle leaders facing...

The ANC’s top six has been mandated to work closely with its integrity committee to tackle claims of corruption against senior party members

The PPE scandal that the Treasury hasn’t touched

Many government officials have been talking tough about dealing with rampant corruption in PPE procurement but the majority won't even release names of who has benefited from the R10-billion spend

press releases

Loading latest Press Releases…

The best local and international journalism

handpicked and in your inbox every weekday